Volumen | 0 |
|
|||||
News | - |
Finanzwerte SLXNW
Börsenwert | Emittierte Aktien | Float | Erlöse | Gewinn/Verlust | Ertrag je Aktie | Kurs-Gewinn-Verhältnis |
---|---|---|---|---|---|---|
106,28k | - | - | - | 0,38 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News Silexion Therapeutics
Datum | Zeit | Quelle | Überschrift |
---|---|---|---|
30.1.2025 | 15:26 | Edgar (US Regulatory) | Form 8-K - Current report |
28.1.2025 | 14:56 | Edgar (US Regulatory) | Form 8-K - Current report |
17.1.2025 | 12:56 | Edgar (US Regulatory) | Form 8-K - Current report |
17.1.2025 | 12:44 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
16.1.2025 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
15.1.2025 | 22:01 | Edgar (US Regulatory) | Form 8-K - Current report |
15.1.2025 | 12:02 | Edgar (US Regulatory) | Form 8-K - Current report |
14.1.2025 | 23:02 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities.. |
14.1.2025 | 12:19 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities.. |
14.1.2025 | 12:01 | Edgar (US Regulatory) | Form 8-K - Current report |
18.12.2024 | 12:00 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
17.12.2024 | 13:08 | Edgar (US Regulatory) | Form 8-K - Current report |
Forum Silexion Therapeutics
Keine Diskussionen Gefunden.Neuen Thread Erstellen
SLXNW Historisch
Zeitraum † | Handelsbeginn | Hoch | Niedrig | VWAP | Durchsch. Volumen | Änderung | % |
---|---|---|---|---|---|---|---|
1 Woche | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
1 Monat | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
3 Monate | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
6 Monate | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
1 Jahr | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
3 Jahre | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |
5 Jahre | 0,00 | 0,00 | 0,00 | 0,00 | 0 | 0,00 | 0,00% |